Humacyte (Humacyte) Change In Other Working Capital : $-0.05 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Humacyte Change In Other Working Capital?

Humacyte's Change In Other Working Capital for the quarter that ended in Mar. 2024 was $-0.01 Mil. It means Humacyte's Other Working Capital declined by $0.01 Mil from Dec. 2023 to Mar. 2024 .

Humacyte's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was $-0.05 Mil. It means Humacyte's Other Working Capital declined by $0.05 Mil from Dec. 2022 to Dec. 2023 .

Humacyte Change In Other Working Capital Historical Data

The historical data trend for Humacyte's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte Change In Other Working Capital Chart

Humacyte Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Other Working Capital

0.21

-0.16

-0.22

-0.05

Humacyte Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Other Working Capital	Get a 7-Day Free Trial										-0.01	-0.01	-0.01	-0.01	-0.01

Humacyte Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05 Mil.

Humacyte Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Humacyte's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Humacyte (Humacyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

2525 East North Carolina Highway 54, Durham, NC, USA, 27713

Website

https://www.humacyte.com

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

Executives

Laura E Niklason	director, 10 percent owner, officer: President, CEO and Director	35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan	director, 10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
Ayabudge Llc	10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
Heather Ledbetter Prichard	officer: Chief Operating Officer	820 BROWNWICH STREET, WAKE FOREST NC 27587
Michael T. Constantino	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Dale A. Sander	officer: CFO & CCDO	11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
William John Scheessele	officer: Chief Commercial Officer	620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao	officer: Chief Regulatory Officer	12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green	director	3185 SCENIC DRIVE, NAPA CA 94558
Gordon M Binder	director	225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Diane Seimetz	director	JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh	officer: Chief Medical Officer	1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla	director	EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
William Edward Tente	officer: Chief Regulatory Officer	90 DAVIS STREET, SEEKONK MA 02771
Todd Pope	director	C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713